HOME >> BIOLOGY >> NEWS
Movie spies on malaria parasite's sneaky behavior

Malaria has been outsmarting the human immune system for centuries. Now, using real-time imaging to track malaria infections in live mice, researchers have discovered one of the parasite's sneakiest tricks--using dead liver cells to cloak and transport itself back into the bloodstream after leaving the liver.

Robert Mnard, a Howard Hughes Medical Institute (HHMI) international research scholar, and his postdoctoral fellow, Rogerio Amino, at the Institut Pasteur in Paris, filmed the malaria parasite as it transitioned from infecting liver cells to infecting red blood cells. During this stage of the parasite's life cycle, the classic symptoms of malaria high fevers and chills are triggered in people who are infected.

Mnard and Amino collaborated with Volker Heussler at the Bernhard-Nocht Institute for Tropical Medicine in Hamburg, Germany. Their images of the parasite sneaking back into the host's bloodstream--published in advance online in Science Express on August 3, 2006, and scheduled for September 2006 publication in Science--clear up a long-standing puzzle about the malaria parasite's life cycle. The discovery could lead to new ways of treating malaria, a disease that infects 300 million people per year and kills 1 million.

"The parasite has evolved this complex structure. The best image to describe it is the Trojan horse, because it both transports the parasites and camouflages them," said Mnard. Like the ancient Greek warriors who hid inside a giant hollow horse to gain entry to Troy, the malaria parasites wrap themselves in a structure made of liver cell membrane. This membrane cloak enables them to sneak past immune cell sentinels and return to the bloodstream.

The malaria parasite, Plasmodium falciparum, has a complex life cycle. It passes from a mosquito's saliva to a human's blood, and then travels to the liver, where it infects and kills liver cells. After it leaves the liver, the parasite moves back into the
'"/>

Contact: Jennifer Donovan
donovanj@hhmi.org
301-215-8859
Howard Hughes Medical Institute
4-Aug-2006


Page: 1 2 3

Related biology news :

1. Movies reveal that the process of insulating nerves is surprisingly dynamic
2. Molecular spies illuminate drug resistance proteins
3. Edible fish feasts beats malaria
4. Identified mechanism in the malaria parasite to help it adapt to infected individuals
5. CRESIB coordinates an international consortium to fight malaria caused by Plasmodium vivax
6. Key to tackling malaria may lie in bed nets for adults and older children
7. Largest synthetic gene ever built offers insights into anti-malarial drug resistance
8. MIT-led team uncovers malaria mechanism
9. Vaccine hope for malaria
10. Antibody-based therapies effective at controlling malaria
11. Researchers identify key protein in immune response to malaria and TB

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Movie spies malaria parasite sneaky behavior

(Date:5/22/2015)... OXFORD, CT , May 22, 2015  NXT-ID, Inc. ... from June 1st, it will be ending its promotional pricing ... www.wocketwallet.com . Laurence Savin , Head of ... our exclusive promotional pricing until the end of May. To ... at wocketwallet.com/invite and when we open the store on June ...
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
(Date:5/26/2015)... May 26, 2015 Tianyin Pharmaceutical Inc. (NYSE ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... the Company,s Annual Meeting of Shareholders for fiscal year ... held at the Company,s office located in ... 9:00 AM (local time in Chengdu, China ...
(Date:5/26/2015)... 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced today ... at Shutters on the Beach in Santa ... of the Company,s innovative Metronomic Biofeedback Pump (MBP), a ... chemotherapy over time to a target site of the ... biofeedback system in real-time.  ...
(Date:5/26/2015)... May 26, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral ... the study protocol for the company,s Phase IIb trial ... Food and Drug Administration (FDA). The submission was made ... The Phase IIb study of ORMD-0801 for ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Just the ... a long-standing unmet biomedical need does not guarantee immediate ... problem that has seen many prior failures is often ... acceptance and use is an irony that is often ... small, new start-up company, Asymmetrex has found ...
Breaking Biology Technology:TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3
Cached News: